bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: Involvement of ERK1/ERK2 activity

Daniela Trisciuoglio, Angela Iervolino, Antonio Candiloro, Gabriella Fibbi, Maurizio Fanciulli, Uwe Zangemeister-Wittke, Gabriella Zupi, Donatella Del Bufalo

Research output: Contribution to journalArticle

Abstract

We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.

Original languageEnglish
Pages (from-to)6737-6745
Number of pages9
JournalJournal of Biological Chemistry
Volume279
Issue number8
DOIs
Publication statusPublished - Feb 20 2004

Fingerprint

Urokinase Plasminogen Activator Receptors
Extracellular Signal-Regulated MAP Kinases
Chemical activation
Cells
Neoplasms
Melanoma
Phosphorylation
Up-Regulation
DNA
Phosphotransferases
Plicamycin
Sp1 Transcription Factor
Breast Neoplasms
Proteins
Protein Stability
Antisense Oligonucleotides
Serine
Vascular Endothelial Growth Factor A
Tumors
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry

Cite this

bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation : Involvement of ERK1/ERK2 activity. / Trisciuoglio, Daniela; Iervolino, Angela; Candiloro, Antonio; Fibbi, Gabriella; Fanciulli, Maurizio; Zangemeister-Wittke, Uwe; Zupi, Gabriella; Del Bufalo, Donatella.

In: Journal of Biological Chemistry, Vol. 279, No. 8, 20.02.2004, p. 6737-6745.

Research output: Contribution to journalArticle

Trisciuoglio, Daniela ; Iervolino, Angela ; Candiloro, Antonio ; Fibbi, Gabriella ; Fanciulli, Maurizio ; Zangemeister-Wittke, Uwe ; Zupi, Gabriella ; Del Bufalo, Donatella. / bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation : Involvement of ERK1/ERK2 activity. In: Journal of Biological Chemistry. 2004 ; Vol. 279, No. 8. pp. 6737-6745.
@article{d5381aefa898441fb319bf2d5e28cc1f,
title = "bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: Involvement of ERK1/ERK2 activity",
abstract = "We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.",
author = "Daniela Trisciuoglio and Angela Iervolino and Antonio Candiloro and Gabriella Fibbi and Maurizio Fanciulli and Uwe Zangemeister-Wittke and Gabriella Zupi and {Del Bufalo}, Donatella",
year = "2004",
month = "2",
day = "20",
doi = "10.1074/jbc.M308938200",
language = "English",
volume = "279",
pages = "6737--6745",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "8",

}

TY - JOUR

T1 - bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation

T2 - Involvement of ERK1/ERK2 activity

AU - Trisciuoglio, Daniela

AU - Iervolino, Angela

AU - Candiloro, Antonio

AU - Fibbi, Gabriella

AU - Fanciulli, Maurizio

AU - Zangemeister-Wittke, Uwe

AU - Zupi, Gabriella

AU - Del Bufalo, Donatella

PY - 2004/2/20

Y1 - 2004/2/20

N2 - We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.

AB - We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor UO126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.

UR - http://www.scopus.com/inward/record.url?scp=1342325424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342325424&partnerID=8YFLogxK

U2 - 10.1074/jbc.M308938200

DO - 10.1074/jbc.M308938200

M3 - Article

C2 - 14660675

AN - SCOPUS:1342325424

VL - 279

SP - 6737

EP - 6745

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 8

ER -